Evidence map›Paper›PMID 41353334›Full record

ArticleBMC cancer2025

Cyclin B2 facilitates glycolysis and tumor progression in pancreatic ductal adenocarcinoma by promoting histone lactylation.

Bin Ma, Xiangjie Li, Zhen Ma, Zhenyu Yin, Lei Gao, Yuhan Wang, Jianming Shi, Xiaolong Liu, Hao Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bin Ma *The Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Xiangjie Li *The Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Zhen MaThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Zhenyu YinThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Lei GaoThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Yuhan WangThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Jianming ShiThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Xiaolong LiuThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Hao ChenThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China. ery_chenh@lzu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCyclin B2 (CCNB2), a member of the cyclin family, plays a crucial role in glycolysis and the progression of pancreatic ductal adenocarcinoma (PDAC). Lactate-dependent histone modifications, particularly histone lactylation, have emerged as novel markers associated with glycolysis. However, the specific mechanisms by which CCNB2 influences histone lactylation in PDAC remain unclear.

methodsWe investigated the involvement of CCNB2 in PDAC growth and progression using glycolysis inhibitors in vivo and in vitro. The expression levels of CCNB2 in PDAC were assessed through bioinformatics analysis, Western blotting, and immunohistochemistry. Additionally, we analyzed the correlation between CCNB2 expression and patient prognosis using online databases. By manipulating CCNB2 expression in PDAC cells, we examined changes in malignant biological phenotypes. Finally, we explored the relationship between CCNB2 and histone lactylation (specifically H3K18la) by investigating its interactions with LDHA/LDHB and TTK/BUB1B.

resultsGlycolytic inhibitors significantly suppressed PDAC cell proliferation both in vitro and in vivo, accompanied by reduced CCNB2 expression. Analysis of online databases revealed that CCNB2 expression was markedly elevated in PDAC tissues, and patients with high CCNB2 expression exhibited poorer prognoses. Further experiments confirmed higher CCNB2 expression in PDAC cells compared to normal cells and tissues. Knockdown of CCNB2 significantly inhibited PDAC cell proliferation, invasion, and migration, while reducing the expression of glycolytic-related proteins HK II, GLUT1, and PKM2, potentially via the PI3K/AKT signaling pathway. CCNB2 knockdown also decreased the expression of LDHA and LDHB, downregulated H3K18la levels, reduced TTK and BUB1B expression, and lowered lactic acid production.

conclusionThe glycolysis-CCNB2-H3K18la-TTK/BUB1B signaling axis exacerbates the malignant progression of PDAC, providing insights into potential lactylation-based therapeutic strategies for this disease.

Indexed as

Carcinoma, Pancreatic DuctalCyclin B2GlycolysisHistonesPancreatic NeoplasmsAnimalsCell Line, TumorCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudePrognosisCCNB2 protein, humanCyclin B2HistonesCCNB2GlycolysisH3K18laHistone lactylationPancreatic ductal adenocarcinoma

Identifiers

PMID41353334
PMCPMC12797688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.